Célia Lebreton1, Justine Bacchetta1,2, Frédérique Dijoud2,3, Lucie Bessenay4, Véronique Fremeaux-Bacchi5, Anne Laure Sellier-Leclerc6. 1. Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Centre de Référence des Maladies Rénales Rares Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 boulevard Pinel, 69677, Bron, France. 2. Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France. 3. Laboratoire d'Anatomopathologie, Groupe Hospitalier Est, Hospices Civils de Lyon, Bron, France. 4. Service de Pédiatrie, CHU Clermont Ferrand, Clermont Ferrand, France. 5. Laboratoire d'Immunologie, Hôpital Georges Pompidou, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France. 6. Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Centre de Référence des Maladies Rénales Rares Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 boulevard Pinel, 69677, Bron, France. anne-laure.sellier-leclerc@chu-lyon.fr.
Abstract
BACKGROUND: Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe glomerular disease. DIAGNOSIS AND TREATMENT: Patients 1, 2 and 3 were diagnosed with nephritic syndrome with alternative complement pathway activation (low C3, C3Nef-positive) and C3G at the age of 9, 13 and 12 years, respectively. Treatment with eculizumab normalized proteinuria within 1, 2 and 7 months, respectively. Proteinuria relapsed when eculizumab was withdrawn, but the re-introduction of eculizumab normalized proteinuria. Patient 4 was diagnosed with C3G at 9 years of age, with progression to end-stage renal disease within 2 years, followed by a first renal transplantation (R-Tx) with early disease recurrence and graft loss within 39 months. After a second R-Tx, she rapidly presented with biological and histological recurrence: therapy with eculizumab was started, with no effect on proteinuria after 5 months, in a complex clinical setting (i.e. association of C3G recurrence, humoral rejection and BK nephritis). Eculizumab was withdrawn due to multiple viral reactivations, but the re-introduction of the drug a few months later enabled a moderate decrease in proteinuria. CONCLUSION: These cases illustrate the efficacy of eculizumab, at least on native kidneys, in paediatric C3G. However, larger international studies are warranted to confirm the benefit and safety of eculizumab therapy.
BACKGROUND:Eculizumab may be used to treat C3-glomerulopathy (C3G), a rare but severe glomerular disease. DIAGNOSIS AND TREATMENT: Patients 1, 2 and 3 were diagnosed with nephritic syndrome with alternative complement pathway activation (low C3, C3Nef-positive) and C3G at the age of 9, 13 and 12 years, respectively. Treatment with eculizumab normalized proteinuria within 1, 2 and 7 months, respectively. Proteinuria relapsed when eculizumab was withdrawn, but the re-introduction of eculizumab normalized proteinuria. Patient 4 was diagnosed with C3G at 9 years of age, with progression to end-stage renal disease within 2 years, followed by a first renal transplantation (R-Tx) with early disease recurrence and graft loss within 39 months. After a second R-Tx, she rapidly presented with biological and histological recurrence: therapy with eculizumab was started, with no effect on proteinuria after 5 months, in a complex clinical setting (i.e. association of C3G recurrence, humoral rejection and BK nephritis). Eculizumab was withdrawn due to multiple viral reactivations, but the re-introduction of the drug a few months later enabled a moderate decrease in proteinuria. CONCLUSION: These cases illustrate the efficacy of eculizumab, at least on native kidneys, in paediatric C3G. However, larger international studies are warranted to confirm the benefit and safety of eculizumab therapy.
Authors: F González-Roncero; M Suñer; G Bernal; V Cabello; M Toro; P Pereira; M Angel Gentil Journal: Transplant Proc Date: 2012-11 Impact factor: 1.066
Authors: Cristina Rabasco; Teresa Cavero; Elena Román; Jorge Rojas-Rivera; Teresa Olea; Mario Espinosa; Virginia Cabello; Gema Fernández-Juarez; Fayna González; Ana Ávila; José María Baltar; Montserrat Díaz; Raquel Alegre; Sandra Elías; Monserrat Antón; Miguel Angel Frutos; Alfonso Pobes; Miguel Blasco; Francisco Martín; Carmen Bernis; Manuel Macías; Sergio Barroso; Alberto de Lorenzo; Gema Ariceta; Manuel López-Mendoza; Begoña Rivas; Katia López-Revuelta; José María Campistol; Santiago Mendizábal; Santiago Rodríguez de Córdoba; Manuel Praga Journal: Kidney Int Date: 2015-07-29 Impact factor: 10.612
Authors: Sudarsana De; Dana Al-Nabhani; Paul Thorner; Daniel Cattran; Tino D Piscione; Christoph Licht Journal: Pediatr Nephrol Date: 2008-10-30 Impact factor: 3.714
Authors: Keri A Drake; Natalie Ellington; Jyothsna Gattineni; Jose R Torrealba; Allen R Hendricks Journal: Pediatr Nephrol Date: 2019-10-30 Impact factor: 3.714
Authors: Monica S Y Ng; Kelly McClymont; Naomi McCallum; Rahul Dua; Katherine Holman; Bruce Bennetts; Gladys Ho; Chirag Patel; Andrew J Mallett Journal: Kidney Int Rep Date: 2018-04-22
Authors: Melissa Muff-Luett; Keia R Sanderson; Rachel M Engen; Rima S Zahr; Scott E Wenderfer; Cheryl L Tran; Sheena Sharma; Yi Cai; Susan Ingraham; Erica Winnicki; Donald J Weaver; Tracy E Hunley; Stefan G Kiessling; Meredith Seamon; Robert Woroniecki; Yosuke Miyashita; Nianzhou Xiao; Abiodun A Omoloja; Sarah J Kizilbash; Asif Mansuri; Mahmoud Kallash; Yichun Yu; Ashley K Sherman; Tarak Srivastava; Carla M Nester Journal: Pediatr Nephrol Date: 2021-03-10 Impact factor: 3.714